OCGN Earnings Date: Nov 4, 2026 (Estimated) — Ocugen, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is OCGN's next earnings date?
Ocugen, Inc. (OCGN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.06 on revenue of $1.3M.
How did OCGN do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Ocugen, Inc. posted EPS of -$0.07 versus the -$0.05 estimate, a miss of 40.0%. Revenue was $1.5M against a $888,833 estimate. The stock's 1-day post-earnings move was -3.1%.
How much does OCGN stock move after earnings?
OCGN beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.3% (up or down) in the day after earnings.
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.05 | -0.07 | -40.00% | $1.5M | ❌ Miss | -3.13% | +9.38% | +5.47% |
| 2026-05-05 | Q1 2026 | -0.05 | -0.06 | -20.00% | $1.5M | ❌ Miss | -19.46% | -20.00% | -29.73% |
| 2026-03-04 | Q4 2025 | -0.06 | -0.06 | +0.00% | $-193,000 | ➖ Inline | +5.38% | -4.84% | -3.76% |
| 2025-11-05 | Q3 2025 | -0.05 | -0.07 | -40.00% | $1.8M | ❌ Miss | -1.40% | -6.99% | -13.29% |
| 2025-08-01 | Q2 2025 | -0.05 | -0.05 | +0.00% | $1.4M | ➖ Inline | -3.53% | -2.91% | -0.97% |
| 2025-03-05 | Q4 2024 | -0.05 | -0.05 | +0.00% | $764,000 | ➖ Inline | -2.80% | -7.36% | +16.78% |
| 2024-11-08 | Q3 2024 | -0.05 | -0.05 | +0.00% | $1.1M | ➖ Inline | -8.69% | -7.41% | -17.67% |
| 2024-05-14 | Q1 2024 | -0.06 | -0.05 | +16.67% | $1.0M | ✅ Beat | -6.08% | +6.08% | -14.92% |
Showing last 8 quarters.